Nicotine in Neurodegenerative and Neuropsychiatric Disorders: Mechanisms and Clinical Evidence.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical mechanisms and clinical evidence without systematic review methodology
PubMed 42545429 · doi:10.1007/s11064-026-04845-0
What was done
This narrative review synthesized preclinical and clinical evidence examining the neuromodulatory and neuroprotective actions of nicotine and nicotinic acetylcholine receptor signaling across neurodegenerative and neuropsychiatric conditions, including Parkinson's disease, Alzheimer's disease, schizophrenia, ADHD, depression, and PTSD.
What was found
The abstract reports no quantitative results, sample sizes, or effect estimates. It qualitatively describes mechanisms including neurotransmitter modulation, neuroinflammation regulation, and synaptic plasticity, while noting translational challenges related to addictive potential and receptor desensitization.
Why it matters
It synthesizes the mechanistic rationale for targeting nicotinic acetylcholine receptors in central nervous system disorders and highlights selective receptor ligands as potential therapeutic strategies.
Limits
As a narrative review, it lacks systematic search criteria, explicit inclusion/exclusion protocols, and meta-analytic pooling. The abstract provides no empirical numbers, human trial details, or effect sizes.
Cited by
- partial Nicotine exerts protective effects against Parkinson's disease and Alzheimer's disease.